Cyprien Rivier, MD, MSc
Associate Research ScientistCards
About
Research
Publications
2025
APOE ε4 and Risk of Intracranial Hemorrhage in Patients With Atrial Fibrillation Taking Apixaban
Clocchiatti-Tuozzo S, Rivier C, Renedo D, Huo S, de Havenon A, Hawkes M, Gilmore E, Schwamm L, Sheth K, Gill T, Falcone G. APOE ε4 and Risk of Intracranial Hemorrhage in Patients With Atrial Fibrillation Taking Apixaban. JAMA Neurology 2025, 82 PMID: 40549373, PMCID: PMC12186128, DOI: 10.1001/jamaneurol.2025.0182.Peer-Reviewed Original ResearchRisk of intracranial hemorrhagePopulation-based studyYears of follow-up dataApo E4Cox proportional hazards modelsAPOE e4 alleleIntracranial hemorrhageRisk prediction scoreCerebral amyloid angiopathyClinical decision-makingProportional hazards modelAtrial fibrillationIncreased risk of ICHMultivariate Cox proportional hazards modelMain OutcomesIncident intracranial hemorrhageEuropean ancestryCohort studyInclusion criteriaHistory of ischemic strokeAmyloid angiopathyE4 variantHazards modelIncreased riskE4 alleleAcute Ischemic Stroke Risk Following Cardiac Interventions in the United States From 2016 to 2021
Koo A, Zhou L, Hameed I, Rivier C, Clocchiatti-Tuozzo S, Kamel H, Falcone G, Ney J, Sharma R, Matouk C, Yaghi S, Sheth K, de Havenon A. Acute Ischemic Stroke Risk Following Cardiac Interventions in the United States From 2016 to 2021. Neurology 2025, 105: e213766. PMID: 40493873, PMCID: PMC12165311, DOI: 10.1212/wnl.0000000000213766.Peer-Reviewed Original ResearchConceptsIntervention hospitalsSurvey weightsNon-Hispanic black ethnicityNIH Stroke ScaleStroke riskIschemic strokeFactors associated with ischemic strokeAssociated with female sexCardiac interventionsIschemic stroke riskIncidence of ischemic strokeVariables associated with riskRate of ischemic strokeNational Inpatient SampleHigh-risk populationDiagnosis-related groupsIntervention patientsCross-sectional cohortUnited StatesAcute ischemic stroke riskIn-hospital deathRisk of strokeSecondary analysisBlack ethnicityInpatient mortalityThe Brain Care Score and its associations with cardiovascular disease and cancer
Senff J, Rivier C, Tack R, Tan B, Kimball T, Brouwers H, Newhouse A, Fricchione G, Tanzi R, Yechoor N, Chemali Z, Anderson C, Rosand J, Falcone G, Singh S. The Brain Care Score and its associations with cardiovascular disease and cancer. Family Practice 2025, 42: cmaf034. PMID: 40464807, DOI: 10.1093/fampra/cmaf034.Peer-Reviewed Original ResearchConceptsLate-life depressionIncidence of cardiovascular diseaseCare scoresCardiovascular diseaseUK Biobank (UKBCases of cardiovascular diseaseRisk of dementiaHealth-related behaviorsIncident cardiovascular diseaseModifiable risk factorsCases of cancerCancer typesUKB participantsCox proportional hazards regression analysisProportional hazards regression analysisHazards regression analysisHealthy agingRisk factorsUKBDementiaRegression analysisFollow-upParticipantsAge-related brain diseasesBaselineDifferent Responses to Blood Pressure Reduction in Lobar and Deep Intracerebral Hemorrhage
Clocchiatti-Tuozzo S, Rivier C, Qureshi A, Renedo D, Huo S, Matouk C, Petersen N, de Havenon A, Sheth K, Rabinstein A, Falcone G, Hawkes M. Different Responses to Blood Pressure Reduction in Lobar and Deep Intracerebral Hemorrhage. Neurocritical Care 2025, 1-9. PMID: 40293696, DOI: 10.1007/s12028-025-02269-2.Peer-Reviewed Original ResearchRenal adverse eventsDeep intracerebral hemorrhageIntensive BP reductionRisk of renal adverse eventsRisk of HEHematoma expansionBP reductionATACH-2Intracerebral hemorrhageLobar intracerebral hemorrhageFunctional outcomesAntihypertensive Treatment of Acute Cerebral Hemorrhage IIAcute spontaneous intracerebral hemorrhageAcute intracerebral hemorrhageSpontaneous intracerebral hemorrhageAssociated with reduced riskUnfavorable functional outcomeBlood pressure reductionRandomized clinical trialsMultivariate logistic regression resultsPost hoc analysisAntihypertensive treatmentAdverse eventsClinical trialsIncreased riskPolygenic Resistance to Vascular Risk Factor Control in Stroke Survivors (S30.006)
Huo S, Rivier C, Clocchiatti-Tuozzo S, Renedo D, Torres-Lopez V, Sunmonu N, Petersen N, De Havenon A, Sheth K, Falcone G. Polygenic Resistance to Vascular Risk Factor Control in Stroke Survivors (S30.006). Neurology 2025, 104 DOI: 10.1212/wnl.0000000000208802.Peer-Reviewed Original ResearchIntegrated Genomic and Proteomic Drug Target Discovery for Vascular Dementia and Alzheimer’s Disease (P3-3.015)
Huo S, Clocchiatti-Tuozzo S, Magid-Bernstein J, Sharma R, Rangaraju S, Sansing L, Sheth K, Rivier C, Falcone G. Integrated Genomic and Proteomic Drug Target Discovery for Vascular Dementia and Alzheimer’s Disease (P3-3.015). Neurology 2025, 104 DOI: 10.1212/wnl.0000000000211466.Peer-Reviewed Original ResearchIntegrated Genomic, Proteomic, and Transcriptomic Profiling Support Cathepsin-B as a Drug Repurposing Target in Cerebral Small Vessel Disease (S2.001)
Rivier C, Huo S, Clocchiatti-Tuozzo S, Renedo D, Sharma R, Payabvash S, Rangaraju S, Dong X, Sheth K, Sansing L, Falcone G. Integrated Genomic, Proteomic, and Transcriptomic Profiling Support Cathepsin-B as a Drug Repurposing Target in Cerebral Small Vessel Disease (S2.001). Neurology 2025, 104 DOI: 10.1212/wnl.0000000000211788.Peer-Reviewed Original ResearchPolygenic Risk Factor Profiling and Risk of Intracerebral Hemorrhage In Patients with Atrial Fibrillation on Apixaban (P9-13.008)
Clocchiatti-Tuozzo S, Rivier C, Huo S, Gilmore E, Shoamanesh A, Kamel H, Murthy S, Ohno-Machado L, Sheth K, Gill T, Falcone G. Polygenic Risk Factor Profiling and Risk of Intracerebral Hemorrhage In Patients with Atrial Fibrillation on Apixaban (P9-13.008). Neurology 2025, 104 DOI: 10.1212/wnl.0000000000212525.Peer-Reviewed Original ResearchClinical Trial Emulation Leveraging Genetic Effects: A Proof-of-Concept Application to SPRINT (P8-11.005)
Clocchiatti-Tuozzo S, Rivier C, Huo S, Shoamanesh A, Kamel H, Murthy S, De Havenon A, Sansing L, Gill T, Sheth K, Falcone G. Clinical Trial Emulation Leveraging Genetic Effects: A Proof-of-Concept Application to SPRINT (P8-11.005). Neurology 2025, 104 DOI: 10.1212/wnl.0000000000212613.Peer-Reviewed Original ResearchImpact of Social Determinants of Health on Outcomes of Nontraumatic Subarachnoid Hemorrhage
Renedo D, Rivier C, Koo A, Clocchiatti‐Tuozzo S, Huo S, Sujijantarat N, Torres‐Lopez V, Hebert R, Schwamm L, de Havenon A, Gunel M, Matouk C, Falcone G, Sheth K. Impact of Social Determinants of Health on Outcomes of Nontraumatic Subarachnoid Hemorrhage. Journal Of The American Heart Association 2025, 14: e037199. PMID: 40194963, PMCID: PMC12132901, DOI: 10.1161/jaha.124.037199.Peer-Reviewed Original ResearchConceptsSocial determinants of healthSocial deprivation indexDeterminants of healthImpact of social determinants of healthDeprivation indexLength of stayInfluence of social determinants of healthOdds ratioDischarge dispositionHigher social deprivation indexAssociated with reduced oddsAverage length of stayVascular risk factorsAssociated with longer lengthSocial determinantsSignificant health burdenEstimate associationsIn-hospital deathNontraumatic subarachnoid hemorrhageSocioeconomic levelHealth burdenOverall mortality rateDecreased deathRisk factorsHealth
News
News
- June 24, 2025
Announcing the Center for Brain & Mind Health 2025 Pilot Grant Program Awardees
- November 20, 2024
Brain Bleeds: How Biological Sex Affects Severity and Outcomes
- July 15, 2024
Rivier Receives Ralph L. Sacco Scholarship for Brain Health
- July 05, 2023
Cyprien Rivier, MD, MSc Wins ESOC Young Research Investigator Award in Stroke
Get In Touch
Contacts
Mobile Phone Number